Key Highlights
- The disease control rate was 88%, or 38 of 43 patients, across Parts A, B and C as of October 1, 2026.
- Part C enrollment has been completed across seven countries, including the United States.
- The company cited a 25% to 35% disease control range for standard third-line chemotherapy regimens.
- A pivotal Phase 3 trial, THIO-104, is advancing with a 2027 interim survival analysis expected.
MAIA Biotechnology, Inc. (NYSEAM:MAIA), a clinical-stage biopharmaceutical company focused on targeted immunotherapies for cancer, released updated interim efficacy data from Part C of its Phase 2 THIO-101 expansion trial. The study evaluates ateganosine, a telomere-targeting therapy, as a third-line treatment for advanced non-small cell lung cancer, or NSCLC.
The trial enrolls patients who were nonresponsive to, or progressed after, prior immune checkpoint inhibitor therapy and chemotherapy. The company said the Part C data are intended to confirm results observed in Parts A and B of the study.
The announcement also summarizes the program’s status, including the completion of Part C enrollment and the progress of the Phase 3 trial in the same patient population.
Trial Design and Patient Population
Patients receive ateganosine at 180mg followed by cemiplimab, sold as Libtayo, in cycles of 21 days. The company said the sequence is designed to enhance and prolong the antitumor immune response by pairing its agent with PD-(L)1 inhibition.
THIO-101 is a multicenter, open-label, dose-finding Phase 2 trial. Part C enrolled patients in Hungary, Poland, Turkey, Georgia, Romania, Taiwan and the United States, and enrollment in that part has been completed.
The trial’s open-label design means both investigators and patients know which treatment is being given. The company said the trial enrolled patients across several countries, which broadens the patient pool beyond a single region.
The company described THIO-101 as the first trial designed to evaluate the agent’s anti-tumor activity in this setting, and the dose-finding structure is intended to identify the dosing level for later studies.
Interim Efficacy Results
For Parts A, B and C combined, as of October 1, 2026, the observed disease control rate for third-line NSCLC patients was 88%, or 38 of 43 patients in the efficacy-evaluable population with at least one tumor scan after treatment began. The company contrasted that figure with a reported 25% to 35% disease control range for standard third-line chemotherapy.
Chief executive Vlad Vitoc said the company views disease control rate as a surrogate for overall survival, citing a historical meta-analysis and the company’s own analysis. The figures are interim, and the company said the sample is still growing as the trial matures.
The company said consistent results across Parts A, B and C are central to its case for the program, while noting that the sample size increased in Part C. The release did not provide duration-of-response or survival data for the expanded cohort.
Regulatory Path and Pipeline Context
MAIA said the Part C data may support an Accelerated Approval filing with the U.S. Food and Drug Administration. The company has ateganosine under the agency’s Fast Track designation, a program that facilitates development and review of drugs for serious conditions.
The pivotal Phase 3 trial, THIO-104, enrolls the same third-line population as THIO-101 Part C and is advancing toward regulatory milestones, including a 2027 interim survival analysis. The release did not provide a timeline for a potential approval decision.
The company’s pipeline description says its telomere-targeting approach activates innate and adaptive immune responses in in vivo cancer models. The release presents those findings as preclinical results rather than human trial data.
The release links the Part C data to a possible accelerated approval filing but does not set a date for submitting that application, and it does not state the number of additional patients the company expects to need.
Final Word
MAIA’s interim report describes an 88% disease control rate across 43 evaluable patients in its third-line NSCLC program, with enrollment in Part C now complete. The results are preliminary, and the sample remains small relative to the Phase 3 trial that the company is running in the same population.
Further data from Part C, along with the 2027 interim survival analysis from THIO-104, will determine how the program’s results develop. The company has stated that the Part C data may support an accelerated approval filing, a step that will depend on regulatory review.






Please wait processing your request...